47 related articles for article (PubMed ID: 29414416)
1. Stem Cell Responsiveness to Imatinib in Chronic Myeloid Leukemia.
Lahlil R; Aries A; Scrofani M; Zanetti C; Hennequin D; Drénou B
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38068992
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option.
Dolinska M; Cai H; Månsson A; Shen J; Xiao P; Bouderlique T; Li X; Leonard E; Chang M; Gao Y; Medina JP; Kondo M; Sandhow L; Johansson AS; Deneberg S; Söderlund S; Jädersten M; Ungerstedt J; Tobiasson M; Östman A; Mustjoki S; Stenke L; Le Blanc K; Hellström-Lindberg E; Lehmann S; Ekblom M; Olsson-Strömberg U; Sigvardsson M; Qian H
Blood; 2023 Jul; 142(1):73-89. PubMed ID: 37018663
[TBL] [Abstract][Full Text] [Related]
3. Targeting mitochondrial bioenergetics by combination treatment with imatinib and dichloroacetate in human erythroleukemic K‑562 and colorectal HCT‑116 cancer cells.
Kakafika MG; Lyta AA; Gavriilidis GI; Tsiftsoglou SA; Miliotou AN; Pappas IS; Vizirianakis IS; Papadopoulou LC; Tsiftsoglou AS
Int J Oncol; 2024 Apr; 64(4):. PubMed ID: 38426621
[TBL] [Abstract][Full Text] [Related]
4. A Deeply Quiescent Subset of CML LSC depend on FAO yet Avoid Deleterious ROS by Suppressing Mitochondrial Complex I.
Chimge NO; Chen MH; Nguyen C; Zhao Y; Wu X; Gonzalez PG; Ogana H; Hurwitz S; Teo JL; Chen X; Du J; Jin V; Kim YM; Ono M; Argüello RJ; Kahn M
Curr Mol Pharmacol; 2024; 17(1):e060923220758. PubMed ID: 37691195
[TBL] [Abstract][Full Text] [Related]
5. Vienna Cancer Stem Cell Club (VCSCC): 20 year jubilee and future perspectives.
Valent P; Sadovnik I; Peter B; Ivanov D; Schulenburg A; Hadzijusufovic E; Willmann M; Rülicke T; Herrmann H; Rabitsch W; Karlic H; Gleixner KV; Sperr WR; Hoermann G; Dahlhoff M; Pfeilstöcker M; Keil F; Lion T; Grunt TW
Expert Rev Hematol; 2023; 16(9):659-670. PubMed ID: 37493441
[TBL] [Abstract][Full Text] [Related]
6. Targeting the Extracellular Signal-Regulated Kinase 5 Pathway to Suppress Human Chronic Myeloid Leukemia Stem Cells.
Tusa I; Cheloni G; Poteti M; Gozzini A; DeSouza NH; Shan Y; Deng X; Gray NS; Li S; Rovida E; Dello Sbarba P
Stem Cell Reports; 2018 Oct; 11(4):929-943. PubMed ID: 30245209
[TBL] [Abstract][Full Text] [Related]
7. The Role of SOX Transcription Factors in Ageing and Age-Related Diseases.
Stevanovic M; Lazic A; Schwirtlich M; Stanisavljevic Ninkovic D
Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614288
[TBL] [Abstract][Full Text] [Related]
8. In Vitro Comparison of the Effects of Imatinib and Ponatinib on Chronic Myeloid Leukemia Progenitor/Stem Cell Features.
Tusa I; Cheloni G; Poteti M; Silvano A; Tubita A; Lombardi Z; Gozzini A; Caporale R; Scappini B; Dello Sbarba P; Rovida E
Target Oncol; 2020 Oct; 15(5):659-671. PubMed ID: 32780298
[TBL] [Abstract][Full Text] [Related]
9. Imatinib mesylate affects extracellular ATP catabolism and expression of NTPDases in a chronic myeloid leukemia cell line.
Willig JB; Vianna DRB; Beckenkamp A; Beckenkamp LR; Sévigny J; Wink MR; Buffon A; Pilger DA
Purinergic Signal; 2020 Mar; 16(1):29-40. PubMed ID: 31955347
[TBL] [Abstract][Full Text] [Related]
10. Sensitivity to imatinib of KCL22 chronic myeloid leukemia cell survival/growth and stem cell potential under glucose shortage.
Bono S; Dello Sbarba P; Lulli M
Data Brief; 2018 Oct; 20():1901-1904. PubMed ID: 30294641
[TBL] [Abstract][Full Text] [Related]
11. Selective and effective targeting of chronic myeloid leukemia stem cells by topoisomerase II inhibitor etoposide in combination with imatinib mesylate in vitro.
Liu MY; Wang WZ; Liao FF; Wu QQ; Lin XH; Chen YH; Cheng L; Jin XB; Zhu JY
Cell Biol Int; 2017 Jan; 41(1):16-23. PubMed ID: 27677634
[TBL] [Abstract][Full Text] [Related]
12. Characterization of cancer stem cells in chronic myeloid leukaemia.
Jørgensen HG; Holyoake TL
Biochem Soc Trans; 2007 Nov; 35(Pt 5):1347-51. PubMed ID: 17956348
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of autophagy: a new strategy to enhance sensitivity of chronic myeloid leukemia stem cells to tyrosine kinase inhibitors.
Calabretta B; Salomoni P
Leuk Lymphoma; 2011 Feb; 52 Suppl 1(Suppl 1):54-9. PubMed ID: 21250825
[TBL] [Abstract][Full Text] [Related]
14. Imatinib-mesylate enhances the maintenance of chronic myeloid leukemia stem cell potential in the absence of glucose.
Bono S; Dello Sbarba P; Lulli M
Stem Cell Res; 2018 Apr; 28():33-38. PubMed ID: 29414416
[TBL] [Abstract][Full Text] [Related]
15. Characterization of Imatinib Resistant CML Leukemic Stem/Initiating Cells and Their Sensitivity to CBP/Catenin Antagonists.
Zhao Y; Wu K; Wu Y; Melendez E; Smbatyan G; Massiello D; Kahn M
Curr Mol Pharmacol; 2018; 11(2):113-121. PubMed ID: 28933312
[TBL] [Abstract][Full Text] [Related]
16. Glucose availability in hypoxia regulates the selection of chronic myeloid leukemia progenitor subsets with different resistance to imatinib-mesylate.
Giuntoli S; Tanturli M; Di Gesualdo F; Barbetti V; Rovida E; Dello Sbarba P
Haematologica; 2011 Feb; 96(2):204-12. PubMed ID: 21071498
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
